Celcuity's Gedatolisib Shows Significant Survival Benefits in Advanced Breast Cancer Trial
Event summary
- Celcuity's Phase 3 VIKTORIA-1 trial results for gedatolisib in HR+/HER2- advanced breast cancer published in the Journal of Clinical Oncology on March 9, 2026.
- Gedatolisib triplet (gedatolisib + palbociclib + fulvestrant) reduced disease progression or death risk by 76% vs. fulvestrant alone.
- Median progression-free survival improved by 7.3 months with the triplet and 5.4 months with the doublet (gedatolisib + fulvestrant).
- FDA granted Priority Review for gedatolisib with a PDUFA date of July 17, 2026.
The big picture
Celcuity's positive Phase 3 results for gedatolisib represent a significant advancement in treating HR+/HER2- advanced breast cancer, particularly for patients who have progressed on existing therapies. The data suggest that comprehensive inhibition of the PI3K/AKT/mTOR pathway could overcome resistance mechanisms seen with current single-target inhibitors. The FDA's Priority Review designation underscores the unmet need in this patient population and the potential for gedatolisib to become a practice-changing therapy.
What we're watching
- Regulatory Approval
- Whether the FDA will approve gedatolisib by the July 2026 PDUFA date, potentially opening a new treatment option for HR+/HER2- advanced breast cancer.
- Commercial Strategy
- How Celcuity plans to position gedatolisib in the competitive landscape of HR+/HER2- advanced breast cancer therapies.
- Clinical Development
- The progress of ongoing Phase 3 VIKTORIA-2 and Phase 1/2 CELC-G-201 trials, which could expand gedatolisib's potential indications.
Related topics